Compare MYO & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYO | SPRO |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.9M | 71.6M |
| IPO Year | 2017 | 2017 |
| Metric | MYO | SPRO |
|---|---|---|
| Price | $1.39 | $1.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.67 | N/A |
| AVG Volume (30 Days) | 713.1K | ★ 727.5K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,000,000.00 | $66,802,000.00 |
| Revenue This Year | $9.10 | N/A |
| Revenue Next Year | $13.59 | $300.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40814.79 | 39.24 |
| 52 Week Low | $0.61 | $1.08 |
| 52 Week High | $1.89 | $3.08 |
| Indicator | MYO | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 35.20 |
| Support Level | $0.77 | $1.10 |
| Resistance Level | N/A | $1.29 |
| Average True Range (ATR) | 0.21 | 0.05 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 46.24 | 36.00 |
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.